Tsuneya Ikezu, MD, PhD

Ikezu photoProfessor, Departments of Pharmacology & Experimental Therapeutics and Neurology

Phone: 617-414-2658
Fax: 617-414-2649
Email: tikezu@bu.edu
Location: L-606 B

 

Background

Dr. Tsuneya Ikezu completed his undergraduate education at University of Tokyo School of Science and Arts, Japan. He earned his M. D. in 1991 and Ph.D. degrees from University of Tokyo School of Medicine in 1997. He joined the Boston University School of Medicine’s Department of Pharmacology and Experimental Therapeutics with a joint appointment in the Department of Neurology in 2010 as a Professor. Dr. Ikezu also leads the Laboratory of Molecular Neurotherapeutics. He joined the BU ADC in March 2011.

Research Interests

Dr. Ikezu’s research interests are focused on the role of neuroinflammation in the pathophysiology of dementia and as a potential therapeutic target of Alzheimer’s disease, HIV-associated dementia, and more recently chronic traumatic encephalopathy and encephalomyelopathy. He also studies enzymes that induce phosphorylation and aggregation of neurological disease-associated proteins, such as Alzheimer’s disease, HIV-associated dementia, and frontotemporal dementia.

ADC Role

Dr. Ikezu serves as the principal investigator for extramurally funded studies, such as anti-inflammatory cytokine regulation of beta-amyloidosis, characterization of beta-amyloidosis in immunodeficient animal models, and therapeutic invention on tau-tubulin kinase-1. Dr. Ikezu also facilitates neuroinflammation-related studies within BU ADC community.

Awards/Memberships

Dr. Ikezu is a past recipient of the Vada Oldfield Alzheimer’s Research Award in 2000, the UNMC Distinguished Scientist Award in 2009, and the UNeMed Research Innovation Award in 2009. He serves on several editorial boards, including PLoS One.

Recent Publications

Xu J, Sato S, Okuyama S, Swan RJ, Jacobsen MT, Strunk E, and Ikezu T. Tau-tubulin kinase 1 enhances pre-fibrillar tau aggregation, spatial learning impairment, and motor neuron degeneration in P301L FTDP-17 tau mutant mice. FASEB J [Epub ahead of print]

Xu J, Tsutsumi K, Tokuraku K, Estes KA, Hisanaga SI, Ikezu T. Actin interaction and regulation of cyclin-dependent kinase 5/p35 complex activity. J Neurochem. 2010 May 21. [Epub ahead of print]

Kiyota T, Okuyama S, Swan RJ, Jacobsen MT, Gendelman HE, Ikezu T. CNS expression of anti-Inflammatory cytokine interleukin-4 attenuates Alzheimer’s disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J [Epub ahead of print]

Flaherty DP, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL. Phenolic bis-styrylbenzenes as β-amyloid binding ligands and free radical scavengers. J Med Chem. 2010 Nov 25;53(22):7992-9. Epub 2010 Nov 1.

Kiyota T, Yamamoto M, Schroder B, Jacobsen MT, Swan RJ, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, beta-amyloidosis, and Learning Impairment of APP/PS1 Mice. Mol Ther 17(5):803-809 (2009)  PMCID:  PMC2709991

Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM, Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One. 4:e6197 (2009)

Tokuraku K, Marquardt M, Ikezu T. Real-time imaging and quantification of amyloid-beta peptide aggregates by novel quantum-dot nanoprobes. PLoS One.4:e8492 (2009)

Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky Y, and Ikezu T. Phosphorylation of Claudin-5 and Occludin by Rho Kinase in Brain Endothelial Cells. Am J Pathol 172:521-33 (2008) PMCID: PMC2312373

Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T. Cytokine-mediated inhibition of fibrillar amyloid- peptide degradation by human mononuclear phagocytes. J Immunol 181:3877-86 (2008) PMCID: PMC2603577

Sato S, Xu J, Okuyama S, Martinez LB, Walsh SM, Jacobsen MT, Swan R, Schlautman JD, Ciborowski P, and Ikezu T. Spatial learning impairment, enhanced Cdk5/p35 activity, and down-regulation of NMDA receptor in transgenic mice expressing tau-tubulin kinase 1. J Neurosci 28:14511-21 (2008) PMC journal – in process

Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T. Interferon- β and tumor necrosis factor-a regulate amyloid-β plaque deposition and β-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol 170:680-92 (2007).

Flaherty DP, Walsh SM, Kiyota T, Dong Y, Ikezu T, Vennerstrom JL. Polyfluorinated Styrylbenzene -Amyloid Plaque Binding Ligands. J Med Chem 50:4986-92 (2007).

Gorantla S, Lui J, Sneller H, Dou H, Smith L, Ikezu T, Holguin A, Volsky DJ, Poluektova L, and Gendelman HE. Glatiramer Acetate Immunization Modulates Glial Function and Protects Neurons in a Murine Model of HIV-1 Encephalitis. J Immunol 179:4345-56 (2007).